Ann: AML patient achieves Complete Response in CHM CORE-NK trial, page-42

The P1 CORE-NK mono-agent trial resulted in 1/9 CR rate (11%).

https://www.sciencedirect.com/science/article/pii/S2666636722000641?via%3Dihub

Although early days, the addition of Vactosertib has resulted in 1/3 CR rate (33%).



This probably says a lot more about Vactosertib than it does CORE-NK. The combination of this drug with Pomalidomide resulted in an increase in the 6 month progression free survival of multiple myeloma patients from 20% to 80%.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371138/

This looks to be the standard PH play (IMU) of picking up mediocre assets for cheap, and attempting to find a combination treatment to make the asset commercially viable - all the while rewarding yourself handsomely to the detriment of retail holders.